argenx NV ADR (ARGX)vsMadrigal Pharmaceuticals Inc (MDGL)
ARGX
argenx NV ADR
$891.76
+1.05%
HEALTHCARE · Cap: $54.94B
MDGL
Madrigal Pharmaceuticals Inc
$431.00
+0.16%
HEALTHCARE · Cap: $10.39B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 361% more annual revenue ($5.92B vs $1.28B). ARGX leads profitability with a 31.7% profit margin vs -25.3%. ARGX earns a higher WallStSmart Score of 73/100 (B).
ARGX
Strong Buy73
out of 100
Grade: B
MDGL
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+67.5%
Fair Value
$2566.94
Current Price
$891.76
$1675.18 discount
Intrinsic value data unavailable for MDGL.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 31 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 36.3%
Revenue surging 52.1% year-over-year
Earnings expanding 50.6% YoY
Conservative balance sheet, low leverage
Revenue surging 71.2% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 165.8x book value
Trading at 19.0x book value
0.0% earnings growth
Weak financial health signals
ROE of -62.1% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 31.7% and operating margin at 36.3%. Revenue growth of 52.1% demonstrates continued momentum.
Bull Case : MDGL
The strongest argument for MDGL centers on Revenue Growth. Revenue growth of 71.2% demonstrates continued momentum.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : MDGL
The primary concerns for MDGL are Price/Book, EPS Growth, Piotroski F-Score.
Key Dynamics to Monitor
ARGX profiles as a growth stock while MDGL is a hypergrowth play — different risk/reward profiles.
ARGX carries more volatility with a beta of -0.04 — expect wider price swings.
MDGL is growing revenue faster at 71.2% — sustainability is the question.
ARGX generates stronger free cash flow (749M), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (73/100 vs 31/100), backed by strong 31.7% margins and 52.1% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Madrigal Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic and liver diseases. The company is headquartered in West Conshohocken, Pennsylvania.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?